Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 130

1.

B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure.

Rivellese F, Humby F, Bugatti S, Fossati-Jimack L, Rizvi H, Lucchesi D, Lliso-Ribera G, Nerviani A, Hands RE, Giorli G, Frias B, Thorborn G, Jaworska E, John C, Goldmann K, Lewis MJ, Manzo A, Bombardieri M, Pitzalis C; PEAC- R4RA investigators.

Arthritis Rheumatol. 2019 Nov 29. doi: 10.1002/art.41184. [Epub ahead of print]

PMID:
31785084
2.

Role of biological agents in treatment of rheumatoid arthritis.

Law ST, Taylor PC.

Pharmacol Res. 2019 Dec;150:104497. doi: 10.1016/j.phrs.2019.104497. Epub 2019 Oct 17. Review.

PMID:
31629903
3.

Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC).

Lliso-Ribera G, Humby F, Lewis M, Nerviani A, Mauro D, Rivellese F, Kelly S, Hands R, Bene F, Ramamoorthi N, Hackney JA, Cauli A, Choy EH, Filer A, Taylor PC, McInnes I, Townsend MJ, Pitzalis C.

Ann Rheum Dis. 2019 Dec;78(12):1642-1652. doi: 10.1136/annrheumdis-2019-215751. Epub 2019 Oct 2.

4.

Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM.

Fautrel B, Kirkham B, Pope JE, Takeuchi T, Gaich C, Quebe A, Zhu B, de la Torre I, De Leonardis F, Taylor PC.

J Clin Med. 2019 Sep 5;8(9). pii: E1394. doi: 10.3390/jcm8091394.

5.

Polyurethane-carbon microfiber composite coating for electrical heating of concrete pavement surfaces.

Sassani A, Arabzadeh A, Ceylan H, Kim S, Gopalakrishnan K, Taylor PC, Nahvi A.

Heliyon. 2019 Aug 23;5(8):e02359. doi: 10.1016/j.heliyon.2019.e02359. eCollection 2019 Aug.

6.

Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes.

Lewis MJ, Barnes MR, Blighe K, Goldmann K, Rana S, Hackney JA, Ramamoorthi N, John CR, Watson DS, Kummerfeld SK, Hands R, Riahi S, Rocher-Ros V, Rivellese F, Humby F, Kelly S, Bombardieri M, Ng N, DiCicco M, van der Heijde D, Landewé R, van der Helm-van Mil A, Cauli A, McInnes IB, Buckley CD, Choy E, Taylor PC, Townsend MJ, Pitzalis C.

Cell Rep. 2019 Aug 27;28(9):2455-2470.e5. doi: 10.1016/j.celrep.2019.07.091.

7.

Patients with rheumatoid arthritis acquire sustainable skills for home monitoring: a prospective dual-country cohort study (ELECTOR clinical trial I).

Skougaard M, Bliddal H, Christensen R, Ellegaard K, Nielsen SM, Zavada J, Oreska S, Krogh NS, Holm CC, Hetland ML, Vencovsky J, Røgind H, Taylor PC, Gudbergsen H.

J Rheumatol. 2019 Aug 15. pii: jrheum.181362. doi: 10.3899/jrheum.181362. [Epub ahead of print]

PMID:
31416921
8.

Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.

McInnes IB, Byers NL, Higgs RE, Lee J, Macias WL, Na S, Ortmann RA, Rocha G, Rooney TP, Wehrman T, Zhang X, Zuckerman SH, Taylor PC.

Arthritis Res Ther. 2019 Aug 2;21(1):183. doi: 10.1186/s13075-019-1964-1.

9.

Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol.

Al-Laith M, Jasenecova M, Abraham S, Bosworth A, Bruce IN, Buckley CD, Ciurtin C, D'Agostino MA, Emery P, Gaston H, Isaacs JD, Filer A, Fisher BA, Huizinga TWJ, Ho P, Jacklin C, Lempp H, McInnes IB, Pratt AG, Östor A, Raza K, Taylor PC, van Schaardenburg D, Shivapatham D, Wright AJ, Vasconcelos JC, Kelly J, Murphy C, Prevost AT, Cope AP.

Trials. 2019 Jul 15;20(1):429. doi: 10.1186/s13063-019-3403-7.

10.

Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial.

Taylor PC, Lee YC, Fleischmann R, Takeuchi T, Perkins EL, Fautrel B, Zhu B, Quebe AK, Gaich CL, Zhang X, Dickson CL, Schlichting DE, Patel H, Durand F, Emery P.

J Clin Med. 2019 Jun 12;8(6). pii: E831. doi: 10.3390/jcm8060831.

11.

Rheumatoid arthritis and the emergence of immuno-autonomics.

Taylor PC, Holman AJ.

Rheumatology (Oxford). 2019 Dec 1;58(12):2079-2080. doi: 10.1093/rheumatology/kez216. No abstract available.

PMID:
31177267
12.

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.

Glatt S, Taylor PC, McInnes IB, Schett G, Landewé R, Baeten D, Ionescu L, Strimenopoulou F, Watling MIL, Shaw S.

Ann Rheum Dis. 2019 Aug;78(8):1033-1040. doi: 10.1136/annrheumdis-2018-214943. Epub 2019 Jun 8.

13.

Correction to: Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.

Bingham CO 3rd, Gaich CL, DeLozier AM, Engstrom KD, Naegeli AN, de Bono S, Banerjee P, Taylor PC.

Trials. 2019 Jun 4;20(1):322. doi: 10.1186/s13063-019-3463-8.

14.

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.

Tanaka Y, Fautrel B, Keystone EC, Ortmann RA, Xie L, Zhu B, Issa M, Patel H, Gaich CL, de Bono S, Rooney TP, Taylor PC.

Ann Rheum Dis. 2019 Jul;78(7):890-898. doi: 10.1136/annrheumdis-2018-214529. Epub 2019 Apr 30.

15.

Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial.

Sweet K, Dasgupta B, de Vries D, Gourley I, Hsu B, Loza MJ, Taylor PC.

Ann Rheum Dis. 2019 Oct;78(10):1439-1441. doi: 10.1136/annrheumdis-2019-215183. Epub 2019 Apr 24. No abstract available.

PMID:
31018960
17.

How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target Strategy.

Taylor PC, Balsa Criado A, Mongey AB, Avouac J, Marotte H, Mueller RB.

J Clin Med. 2019 Apr 15;8(4). pii: E515. doi: 10.3390/jcm8040515.

18.

Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?

Baumgart DC, Misery L, Naeyaert S, Taylor PC.

Front Pharmacol. 2019 Mar 28;10:279. doi: 10.3389/fphar.2019.00279. eCollection 2019. Review.

19.

The Clinical Features, Pathogenesis and Methotrexate Therapy of Chronic Chikungunya Arthritis.

Amaral JK, Taylor PC, Teixeira MM, Morrison TET, Schoen RT.

Viruses. 2019 Mar 22;11(3). pii: E289. doi: 10.3390/v11030289. Review.

20.

Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.

Bingham CO 3rd, Gaich CL, DeLozier AM, Engstrom KD, Naegeli AN, de Bono S, Banerjee P, Taylor PC.

Trials. 2019 Mar 22;20(1):182. doi: 10.1186/s13063-019-3272-0. Erratum in: Trials. 2019 Jun 4;20(1):322.

Supplemental Content

Loading ...
Support Center